Distribution of Th1- and Th2-induced Anti-factor VIII IgG Subclasses in Congenital and Acquired Hemophilia Patients

Summary

Development of antibodies (Ab) that inhibit the procoagulant function of factor VIII (fVIII) seriously complicates the treatment of hemophilia A patients. It also causes acquired hemophilia, a rare yet serious autoimmune disease. The design of effective fVIII-specific tolerizing procedures will require elucidation of the role of the different CD4⁺ T cell subsets that drive inhibitor synthesis. To examine the contribution of Th1 and Th2 cells in the anti-fVIII Ab response, we measured the concentration of Th1- and Th2-driven anti-fVIII IgG subclasses in 17 patients with severe hemophilia A and 18 patients with acquired hemophilia. We found that both congenital and acquired hemophilia patients had similar and comparable proportions of Th1- and Th2-induced anti-fVIII Ab, suggesting a more important role of Th1 cells in the immune response to fVIII than previously appreciated. The distribution of anti-fVIII IgG subclasses was stable for periods of up to six months. More intense anti-fVIII Ab responses and higher inhibitor titers correlated with a predominance of Th2-driven subclasses. In contrast, Th1-driven anti-fVIII Ab were predominant in patients who had low anti-fVIII Ab concentrations, even when this was the result of successful immune tolerance or immunosuppressive therapy, which had caused drastic reduction or disappearance of inhibitors.

Thus, synthesis of Th2-driven inhibitors occurs when the anti-fVIII Ab response is intense, while Th1 cells may be involved in the long-term maintenance of anti-fVIII Ab synthesis.

Keywords

Th1 cells - Th2 cells - factor VIII - antibodies - hemophilia A - acquired hemophilia

• References

• 1 Hoyer LW. Hemophilia A. N Engl J Med 1994; 330: 38-47.
• 2 Hoyer LW. The incidence of factor VIII inhibitors in patients with severe hemophilia A. In: Aledort LM, Hoyer LW, Lusher JM, Reisner HM, White GC. eds. Inhibitors to Coagulation Factors. Adv Exp Med Biol. 1995. 386: 35-45.
• 3 Aledort LM. Inhibitors in hemophilia patients: current status and management. Am J Hematol 1994; 47: 208-17.
• 4 Aledort LM. Inhibitors to coagulation: can we afford immune tolerance induction regimens?. Vox Sang 1996; 70: 77-8.
• 5 Cohen AJ, Kessler CM. Acquired inhibitors. Baillieres Clin Haematol 1996; 09: 331-54.
• 6 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII. Thromb Haemost 1981; 45: 200-3.
• 7 Kessler CM, Ludlam CA. for the International Acquired Hemophilia Study Group. The treatment of acquired factor VIII inhibitors: Worldwide experience with porcine factor VIII concentrate. Semin Hematol 1993; 30 (02) (Suppl. 01) 22-7.
• 8 Reding MT, Wu HY, Krampf M, Okita DK, Diethelm-Okita BM, Key NS, Conti-Fine BM. CD4⁺ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999; 82: 509-15.
• 9 Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
• 10 Abbas A, Murphy K, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-93.
• 11 Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997; 18: 263-6.
• 12 Weigle WO, Romball CG. CD4⁺ T-cell subsets and cytokines involved in peripheral tolerance. Immunol Today 1997; 18: 533-8.
• 13 Seder RA, Paul WE. Acquisition of lymphokine-producing phenotype by CD4⁺ T cells. Ann Rev Immunol 1994; 12: 635-73.
• 14 Constant SL, Bottomly K. Induction of Th1 and Th2 CD4⁺ T cell responses: The alternative approach. Ann Rev Immunol 1997; 15: 297-322.
• 15 de Waal Malefyt R, Yssel H, de Vries JE. Direct effects of IL-10 on subsets of human CD4⁺ T cell clones and resting T cells. Specific inhibition of IL-2 production and proliferation. J Immunol 1993; 150: 4754-65.
• 16 Groux H, Bigler M, de Vries JE, Roncarolo M-G. Interleukin-10 induces a long-term antigen-specific anergic state in human CD4⁺ T cells. J Exp Med 1996; 184: 19-29.
• 17 Ding L, Shevach EM. IL-10 inhibits mitogen-induced T cell proliferation by selectively inhibiting macrophage costimulatory function. J Immunol 1992; 148: 3133-9.
• 18 Macatonia SE, Doherty TM, Knight SC, O’Garra A. Differential effect of IL-10 on dendritic cell-induced T cell proliferation and IFN-gamma production. J Immunol 1993; 150: 3755-65.
• 19 Ding L, Linsley PS, Huang LY, Germain RN, Shevach EM. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993; 15: 1224-34.
• 20 Enk AH, Angeloni VL, Udey MC, Katz SI. Inhibition of Langerhans cell antigen-presenting function by IL-10. A role for IL-10 in induction of tolerance. J Immunol 1993; 151: 2390-8.
• 21 O’Garra A, Steinman L, Gijbels K. CD4⁺ T-cell subsets in autoimmunity. Curr Opin Immunol 1997; 09: 872-83.
• 22 Seder RA, Mart T, Sieve MC, Strober W, Letterio JJ, Roberts AB, Kelsall B. Factors involved in the differentiation of TGF-β-producing cells from naive CD4⁺ T cells: IL-4 and IFN- γ have opposing effects, while TGF- β positively regulates its own production. J Immunol 1998; 160: 5719-28.
• 23 O’Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity 1998; 08: 275-83.
• 24 Letterio JL, Roberts AB. Regulation of immune responses by TGF- β. Ann Rev Immunol 1998; 16: 137-61.
• 25 King C, Davies J, Mueller R, Lee MS, Krahl T, Yeung B, O’Connor E, Sarvetnick N. TGF β ₁ alters APC preference, polarizing islet antigen responses toward a Th2 phenotype. Immunity 1998; 08: 601-13.
• 26 Gorham JD, Guler ML, Fenoglio D, Gubler U, Murphy KM. Low dose TGF- β attenuates IL-12 responsiveness in murine Th cells. J Immunol 1998; 161: 1664-70.
• 27 Bright JJ, Sriram S. TGF- β inhibits IL-12-induced activation of Jak-STAT pathway in T lymphocytes. J Immunol 1998; 161: 1772-7.
• 28 Burdin N, Van Kooten C, Galibert L, Abrams JS, Wijdenes J, Banchereau J, Rousset F. Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. J Immunol 1995; 154: 2533-44.
• 29 Rousset F, Peyrol S, Garcia E, Vezzio N, Andujar M, Grimaud JA, Banchereau J. Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not Il-4. Int Immunol 1995; 07: 1243-53.
• 30 Malisan F, Briere F, Bridon JM, Harindranath N, Mills FC, Max EE, Banchereau J, Martinezvaldez H. Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes. J Exp Med 1996; 183: 937-47.
• 31 Kindler V, Zubler RH. Memory, but not naive, peripheral blood B lymphocytes differentiate into Ig-secreting cells after CD40 ligation and costimulation with IL-4 and the differentiation factors IL-2, IL-10 and IL-3. J Immunol 1997; 159: 2085-90.
• 32 Weiner H, Friedman A, Miller A, Khoury SJ, Al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Ann Rev Immunol 1994; 12: 809-37.
• 33 Chen Y, Inobe J, Marks R, Gonnella P, Kuchroo V, Weiner H. Peripheral deletion of antigen-reactive T cells in oral tolerance. Nature 1995; 376: 177-80.
• 34 Chen Y, Inobe J, Kuchroo V, Baron J, Janeway CJ, Weiner H. Oral tolerance in myelin basic protein T-cell receptor transgenic mice: suppression of autoimmune encephalomyelitis and dose-dependent induction of regulatory cells. Proc Natl Acad Sci USA 1996; 93: 388-91.
• 35 Friedman A, Weiner HL. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc Natl Acad Sci USA 1994; 91: 6688-92.
• 36 Gregerson D, Obritsch W, Donoso L. Oral tolerance in experimental autoimmune uveoretinitis. Distinct mechanisms of resistance are induced by low dose vs. high dose feeding protocols. J Immunol 1993; 151: 5751-61.
• 37 Karachunski P, Ostlie N, Okita D, Conti-Fine BM. Protection from experimental myasthenia gravis in C57Bl/6 mice by sniffing of synthetic CD4⁺ T cells epitopes. J Clin Invest 1997; 100: 3027-35.
• 38 Karachunski PI, Ostlie NS, Okita DK, Garman R, Conti-Fine BM. Subcutaneous administration of T epitope sequences of the acetylcholine receptor prevents experimental myasthenia gravis. J Neuroimmunol 1999; 93: 108-21.
• 39 Hoyer LW, Gawry MS, de la Fuente B. Immunochemical characterization of factor VIII inhibitors. In: Factor VIII Inhibitors 1984; 73-85.
• 40 Lavergne JM, Meyer D, Reisner H. Characterization of human anti-factor VIII antibodies purified by immune complex formation. Blood 1976; 48: 931-9.
• 41 Hultin MB, London FS, Shapiro SS, Yount WJ. Heterogeneity of factor VIII antibodies: Further immunochemical and biologic studies. Blood 1977; 49: 807-17.
• 42 Kavanagh ML, Wood CN, Davidson JF. The immunological characterization of human antibodies to factor VIII isolated by immuno-affinity chromatography. Thromb Haemost 1981; 45: 60-4.
• 43 Allain JP, Gaillandre A, Lee H. Immunochemical characterization of antibodies to factor VIII in hemophilic and nonhemophilic patients. J Lab Clin Med 1981; 97: 791-800.
• 44 Fulcher CA, de Graaf Mahoney S, Zimmerman TS. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting. Blood 1987; 69: 1475-80.
• 45 Sanchez-Cuenca JM, Carmona E, Villaneuva MJ, Aznar JA. Immunological characterization of factor VIII inhibitors by a sensitive micro-ELISA method. Thromb Res 1990; 57: 897-908.
• 46 Gilles JGG, Arnout J, Vermylen J, Saint-Remy J-MR. Anti-factor VIII antibodies of hemophilic patients are frequently directed towards nonfunctional determinants and do not exhibit isotypic restriction. Blood 1993; 82: 2452-61.
• 47 Karachunski P, Ostlie N, Okita D, Conti-Fine BM. Interleukine-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4⁺ epitope sequences of the acetylcholine receptor. J Neuroimmunol 1999; 95: 73-84.
• 48 Verbruggen B, Novakova I, Wessels H, Boezman J, van den Berg M, Mauser-Bunschoten E. The Nijmegen modification of the Bethesda assay for FVIII:C inhibitors: improved specificity and reliability. Thromb Haemost 1995; 73: 247-51.
• 49 Bi L, Lawler AM, Antonarakis SF, High KA, Gearhart JD, Kazazian HH. Targeted disruption of the mouse factor VIII gene produces a model of hemophilia A. Nature Genet 1995; 10: 119-21.
• 50 Bi L, Sarkar R, Naas T, Lawler AM, Pain J, Shumaker SL, Bedian V, Kazazian HH. Further characterization of factor VIII-deficient mice created by gene targeting: RNA and protein studies. Blood 1996; 88: 3446-50.
• 51 Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, Hoyer LW, Conti-Fine BM. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-33.
• 52 Sasgary M, Ahmad RU, Schwarz HP, Turecek PL, Reipert BM. Single cell analysis of factor VIII-specific T cells in hemophilic mice after treatment with human factor VIII. Thromb Haemost 2002; 87: 266-72.